3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Mucositis
4
Hematologic Neoplasms
3
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Graft vs Host Disease
1
Interventions
Cyclophosphamide
59
fludarabine phosphate
53
Peripheral Blood Stem Cell Transplantation
43
Tacrolimus
40
Mycophenolic Acid
36
Busulfan
33
Whole-Body Irradiation
32
Antilymphocyte Serum
28
Cyclosporine
27
Methotrexate
25
fludarabine
19
Filgrastim
18
Melphalan
17
Radiotherapy
15
Methylprednisolone
13
Etoposide
12
Cord Blood Stem Cell Transplantation
12
thymoglobulin
11
Sirolimus
11
ruxolitinib
10
Flow Cytometry
10
Psychiatric Rehabilitation
9
Azacitidine
9
Stem Cell Transplantation
7
Granulocyte Colony-Stimulating Factor
7
Decitabine
7
Therapeutics
6
Imatinib Mesylate
6
Cytarabine
6
Cyclosporins
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
angiotensin I (1-7)
×
Other hematologic neoplasm
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled